Epidemiologia e caracterização molecular de Pegivirus humano tipo 1 (HPgV-1) em indivíduos coinfectados pelos vírus da hepatite C (HCV) e/ou vírus da imunodeficiência humana (HIV) / Epidemiology and molecular characterization of human Pegivirus type 1 (HPgV-1) in individuals co-infected with hepatitis C virus (HCV) and / or human immunodeficiency virus (HIV)

O Pegivirus humano 1 (HPgV-1) é um vírus de RNA de fita simples de polaridade positiva membro da família Flaviviridae, e que possui similaridade genômica com o vírus da hepatite C (HCV). No entanto, diferentemente do HCV, o HPgV-1 é linfotrópico e estabelece uma infecção subclínica. Vários estudos relataram que a infecção pelo HPgV-1 está associada à progressão tardia da doença pelo HIV, com indivíduos infectados demonstrando maiores contagens de células TCD4+, menor carga viral do HIV, uma progressão mais lenta para AIDS e, consequentemente, uma expectativa de vida prolongada. Em pacientes com coinfecção crônica por HCV e HIV, o RNA do HPgV-1 foi associado a níveis significativamente mais baixos de ALT e AST e a uma melhora na sobrevida livre de cirrose, sugerindo um efeito benéfico da infecção pelo HPgV-1 em ambas as infecções. Para a melhor compreensão do impacto do HPgV-1 nas co-infecções, se faz necessário conhecer as características epidemiológicas desse vírus. O objetivo deste estudo foi determinar a prevalência e distribuição genotípica do HPgV-1 em doadores de sangue e pacientes HCV e HIV positivos atendidos em um hospital no Rio de Janeiro entre os anos de 2017 a 2018.

Um ensaio de RT-PCR para amplificação específica da região 5'UTR do genoma viral foi realizado em 236 amostras de soro, sendo 56 amostras de coinfecção HCV/HIV, 60 de HCV mono-infectadas, 60 de HIV mono-infectadas e 60 de doadores de sangue. Todas as amostras positivas foram submetidas ao seqüenciamento direto do genoma viral para genotipagem e caracterização molecular. A prevalência geral de HPgV-1 foi de 15,7% (37/236). Maiores frequências de HPgV-1 foram encontradas no grupo de indivíduos com HIV 28,3% (17/60), seguido pelos grupos de indivíduos co-infectados com HCV/HIV (14,3%), doadores de sangue (11,6%) e em co-infecção com HCV (8,3%). A análise filogenética revelou a presença dos genótipos 2a (22,8%), 2b (57,1%), 3 (8,5%) e 1 (8,5%) de HPgV-1. Este é o primeiro estudo que caracteriza a infecção pelo HPgV-1 em pacientes com HCV e HCV/HIV na cidade do Rio de Janeiro e que visa contribuir com maiores informações sobre características epidemiológicas e clínicas do HPgV-1 no curso natural da infecções pelo HCV e/ou HIV. (AU)

Insect microbiomes and insect- specific viruses a new key for understanding the arboviruses diseases? / ¿Los microbiomas de insectos y los virus específicos de insectos son una nueva clave para entender las enfermedades de los arbovirus?

Abstract The last past two decades, there has been a tremendous expansion in the discovery and description of novel insect- specific viruses (ISVs). This has corresponded with progresses in metagenomic analyses for virus revealing and the increasing attention in insect microbiomes. Plentiful of the new ISVs seem to be members of the family Flaviviridae, genus Flavivirus, and are usual in insect populations in wildlife, with a global geographic circulation.

Pegivirus humano: potencial patogénico y riesgo de desarrollo de linfoma no Hodgkin / Human Pegivirus: pathogenic potential and non-Hodgkin lymphoma development risk

Resumen El pegivirus humano (HPgV) es un virus ARN que fue identificado en el año 1995. Actualmente se encuentra clasificado dentro de la familia Flaviviridae, género Pegivirus, relacionado filogenéticamente con el virus de la hepatitis C (VHC). El HPgV es un virus linfotrópico, con replicación en médula ósea, tejidos linfoides, y en células mononucleares de sangre periférica. Este virus se transmite por vía parenteral y sexual. Según estimaciones realizadas, en el mundo existen alrededor de 750 millones de personas infectadas por este agente. Se ha evidenciado que hasta en 25% de los casos se presenta una infección persistente, y aunque se considera que el HPgV es un virus no patogénico, existen evidencias epidemiológicas que sugieren una relación con el desarrollo de desórdenes linfoproliferativos, particularmente linfoma no Hodgkin (LNH). Algunos estudios han reportado una alta prevalencia de HPgV en pacientes con LNH comparado con donantes de sangre y/o pacientes con enfermedades hematológicas no malignas, lo que se asocia a un incremento en el riesgo relativo para el desarrollo de LNH en personas infectadas. De otra parte, existen estudios epidemiológicos que contradicen esta asociación, por lo que el rol de HPgV en la aparición de desórdenes lifoproliferativos es un tema actual de debate. En el presente manuscrito se discute el potencial patogénico derivado de los mecanismos de infección persistente del HPgV, así como las principales evidencias sobre la relación entre el HPgV y el riesgo de desarrollo de LNH.

The human pegivirus (HPgV), classified in the Flaviviridae family - Pegivirus genus, is an RNA virus identified in 1995. HPgV is a lymphotrophic virus, with replication sites in bone marrow and lymphoid tissue, as well as in peripheral blood mononuclear cells (PBMCs). Transmission is through sexual and parenteral routes, and recent estimations suggest nearly 750 million people are infected with HPgV worldwide. Almost 25% of infected individuals can develop persistent infection. Until now, HPgV has been considered a non-pathogenic virus; however, epidemiological studies suggest a potential role in lymphoproliferative diseases, particularly in the development of non-Hodgkin lymphoma (NHL). The evidence of this is controversial and the role of HPgV in lymphomagenesis has not yet been demonstrated. Several studies report a high prevalence of HPgV infection in patients with NHL compared to controls and patients with other hematological diseases. Therefore, analytic studies show that HPgV could be related to an increased risk of NHL development. Conversely, other studies indicate no association between HPgV and NHL, so the role of HPgV in lymphomagenesis is not clear. This review summarizes the main findings related to HPgV's pathogenic potential and association with NHL.

Interacción entre el virus de la inmunodeficiencia humana y el virus GB tipo-C durante el estado de co-infección / Interaction between HIV-1 and GB virus type-C during coinfection status

The human immunodeficiency virus (HIV) infection is one of the most important problems in public health. It is estimated that 3 3 million people are infected around the world. HIV and GBV-C share the same transmission route, being frequent the co-infection. Since both viruses replicate in CD4+ lymphocytes, recent studies have described an interaction. Decreasing of HIV viral load and higher CD4 counts have been observed in co-infected patients, leading a better clinical outcome. Nevertheless, some epidemiological studies have shown contradictory results. Additionally, in vitro models report inhibition of HIV by E1, E2, NS3 and NS5A GBV-C proteins, resulting in a decreasing of p24 antigen. This review summarizes the principal findings about co-infection and mechanisms that have been proposed for HIV-1 inhibition.

La infección por el virus de la inmunodeficiencia humana (VIH) continúa siendo uno de los principales problemas en salud pública; se estima que existen actualmente más de 33 millones de personas infectadas en el mundo. El VIH y el virus GB tipo C (GBV-C) comparten la misma vía de transmisión, por lo que es frecuente encontrar individuos co-infectados. Estudios recientes han descrito un efecto inhibitorio asociado a disminución en la carga viral de VIH, altos recuentos de CD4 y mayor tiempo de sobrevida en pacientes co-infectados, resultando en un mejor pronóstico y menor progreso a SIDA; adicionalmente, estudios in vitro indican que las proteínas virales E1, E2, NS3 y NS5A del GBV-C estarían implicadas en la inhibición del VIH-1. En el presente artículo se revisan los principales aspectos de la co-infección, y se describen los mecanismos propuestos para la inhibición de la replicación del VIH-1 mediada por las proteínas virales del GBV-C.

Actualización en el tratamiento de la Hepatitis C / An update in the therapy of Hepatitis C

La hepatitis C es una enfermedad infecto contagiosa causada por 6 genotipos del virus del mismo nombre que puede responder de manera distinta al tratamiento. El virus de 30 a 38 nm de tamaño, posee una envoltura y una sola cadena de ARN (+), pertenece a la familia Flaviviridae. La hepatitis C constituye un grave problema de salud pública se calcula que las tasas de infectados en la mayoría de los países se encuentra entre el 1,5 y el 3 %, siendo su tratamiento complejo.

Hepatitis C is a communicable disease caused by 6 genotypes of the hepatitis C virus, and this condition may have a variable response to therapy. Viral particles are 30-38 nm long, they have an envelope and single-stranded RNA. The virus belongs to the Flaviviridae family. Hepatitis C is a severe public health problem. It has been estimated that the rate of infected persons in most of the countries lies between 1,5 to 3 per cent, and its therapy is quite complex.

Dengue in India.

Dengue virus belongs to family Flaviviridae, having four serotypes that spread by the bite of infected Aedes mosquitoes. It causes a wide spectrum of illness from mild asymptomatic illness to severe fatal dengue haemorrhagic fever/dengue shock syndrome (DHF/DSS). Approximately 2.5 billion people live in dengue-risk regions with about 100 million new cases each year worldwide. The cumulative dengue diseases burden has attained an unprecedented proportion in recent times with sharp increase in the size of human population at risk. Dengue disease presents highly complex pathophysiological, economic and ecologic problems. In India, the first epidemic of clinical dengue-like illness was recorded in Madras (now Chennai) in 1780 and the first virologically proved epidemic of dengue fever (DF) occurred in Calcutta (now Kolkata) and Eastern Coast of India in 1963-1964. During the last 50 years a large number of physicians have treated and described dengue disease in India, but the scientific studies addressing various problems of dengue disease have been carried out at limited number of centres. Achievements of Indian scientists are considerable; however, a lot remain to be achieved for creating an impact. This paper briefly reviews the extent of work done by various groups of scientists in this country.

Analysis of GB virus C infection among HIV-HCV coinfected patients / Análise da infecção pelo vírus GB-C em pacientes com coinfecção VIH-VHC

The aim of this study was to evaluate the effect of GB virus C on laboratory markers and histological parameters among HIV-seropositive patients coinfected with HCV. Lower degrees of hepatic lesions were observed in the triple-infected patients, in comparison with HIV-HCV coinfected patients who were negative for GBV-C RNA.

O objetivo do estudo foi avaliar o efeito da infecção pelo vírus GB-C em marcadores laboratoriais e parâmetros histológicos em pacientes HIV soropositivos coinfectados com VHC. Menor grau de lesão hepática foi observado nos pacientes com tripla infecção em comparação aos pacientes coinfectados com VIH-VHC negativos para GBV-C RNA.

Tick-borne pathogens and diseases of animals and humans in Thailand.

Tick-borne pathogens in Thailand can cause diseases that result in productivity and economic losses in the livestock sector as well as cause debilitating illnesses in humans and their companion animals. With the advent of molecular techniques, accurate identification of tick-borne pathogens and precise diagnosis of disease is now available. This literature review summarizes the various tick-borne pathogens that have been isolated from ticks and their vertebrate hosts in Thailand, covering those protozoa, rickettsiae, bacteria and viruses most responsible for human and veterinary disease with particular emphasis on those that have been characterized molecularly.

Effect of GBV-C/HIV coinfection on HIV/AIDS disease progression and HIV replication / 病毒学报

Several research groups have recently reported that persistent GB virus C (GBV-C) co-infected with human immunodeficiency virus (HIV) leads to slower AIDSs disease progression than HIV-1 infection alone. However, these findings were not confirmed by several other studies. To investigate the association between GBV-C replication and plasma HIV loads and CD4+ T cell counts, 203 HIV-1 positive former blood/plasma donors(FBDs) were enrolled from Fuyang city of Anhui Province in China. Plasma specimens were collected from them and were tested for GBV-C using RT-PCR and ELISA. Out of 203 specimens, 52 (25.6%) cases were positive for GBV-C, including 35 male (67.3%) and 17 female (32.7%) cases. No significant association was identified between GBV-C infection and CD4+ T-cell counts or between GBV-C infection and HIV viral loads. Since all the subjects studied were naive to ART, the influence of therapy on AIDS disease progression was ruled out in this study. Overall, our data indicated that HIV-1 positive male FBDs were prone to be infected, GBV-C coinfection with HIV-1 does not significantly influence HIV/AIDS disease progression during the late stage of chronic HIV-1 infection.

Prevalência e fatores associados à infecção pelo vírus da diarréia viralbovina na região Sul do Rio Grande do Sul / Prevalence and factors associated with bovine viral diarrhea virus infection in South of Rio Grande do Sul

O presente estudo teve como objetivo estimar a prevalência e determinar os principais fatores associadosà infecção pelo vírus da diarréia viral bovina (BVDV) no rebanho bovino dos municípios de Santa Vitóriado Palmar e Chuí, na região sul do estado do Rio Grande do Sul. Amostras de soro foram submetidas àprova de soroneutralização e, em cada propriedade avaliada, aplicou-se um questionário epidemiológicopara investigar fatores que poderiam estar associados à infecção. As amostras de soro foram coletadasem 85 propriedades, cujos animais apresentavam ou não sinais clínicos de infecção pelo BVDV. Das1.734 amostras de soro analisadas, 1.150 (66,32%) foram positivas com a detecção de bovinossorologicamente positivos em 70 (82,35%) propriedades. Dentre os fatores avaliados, exploração mista,criação extensiva, realização de ordenha mecânica, uso de inseminação artificial ou de inseminaçãoartificial associada à monta natural, uso de piquete de parição e ausência de assistência veterinária,apresentaram significância estatística (P<0,05) associada à soropositividade. Os resultados obtidosdemonstram a expressiva disseminação do BVDV no rebanho bovino dessa região do Rio Grande do Sul.

This study was performed in order to estimate the prevalence of bovine viral diarrhea virus (BVDV), andto determine the main factors related to the prevalence of the infection in cattle of Santa Vitória do Palmarand Chuí counties, in Rio Grande do Sul State. Sera were submitted to the serum neutralization test andan epidemiological questionnaire was filled out in each herd to investigate variables that could beassociated with this infection. The sera samples were collected in 85 farms, with or without clinical signsof BVDV infection. From 1.734 serum samples examined, 1.150 (66.32%) in 70 (82.35%) herds were positive.Variables that were identified as risk factors to seropositivity were mixed (dairy and beef) herds, extensive production, use of mechanical milking, use of artificial insemination or artificial insemination associated with natural service, use of the maternity unit at calving and absence of veterinarian assistance (P<0.05).The results demonstrate the expressive dissemination of the BVDV in cattle of this region in Rio Grande do Sul

Evaluation of HGV viremia prevalence and its co- infection with HBV, HCV, HIV and HTLV-1 in hemophilic patients of Southern Khorassan, Iran

The GB virus-C [GBV-C] and Hepatitis G virus [HGV], collectively known as GBV-C/HGV and transmitted through blood transfusion and blood components. A co-infection of HGV and HCV is often seen in patients with hemophilia. The paucity of information about rate of GBV-C infection among hemophilic patients in Iran promoted the current study. This study was performed on 80 hemophilic patients from south Khorassan branch of Iranian hemophilia society in Birjand. All 80 serum samples were tested for hepatitis B surface antigen [HBs-Ag], Anti HCV, Anti HIV, and Anti HTLV-1. All sera positive for HCVAb were retested by recombinant immunoblot assay as a complementary test. Also, Serum HCV-RNA, HCV genotyping and HGV-RNA were detected. The prevalence of HGV-RNA was 5% [4 of 80]. The prevalence of Anti HCV positive was 26.3% [21 of 80] and HCV- RNA was detected in 80% [17 of 21] of these patients. Co infection of HGV with HCV was 5%. HBsAg and Anti HIV were negative in all of our patients. Anti HTLV-1 was detected in one patient [1.25%]. HGV and HCV are prevalent in South Khorassan hemophilic patients. Prevalence of HGV infection is less than HCV but it is more prevalent than HBV, HIV and HTLV-1 infection

High prevalence of HGV coinfection with HBV or HCV among northeastern Thai blood donors.

Hepatitis G viral (HGV) infection among northeastern Thai blood donors was determined by the nested RT-PCR technique. HGV RNA was amplified by the degenerated helicase primers for a product of the expected size of 83 base pairs were used in this study. Serum samples from 322 of three different categories of northeastern Thai blood donors were included in this study. There were 104 HBsAg and Anti-HCV seronegative blood donors (control group), 100 samples of HBs Ag seropositive blood donors (HBV infected group) and 118 serum samples from anti-HCV seropositive blood donors (HCV infected group). The results demonstrated that HGV RNA was not detected in the control group but was found in 10 individuals (10%) in the HBV infected group and 13 (11%) in the anti-HCV positive blood donors. The prevalences of HGV in both seropositive groups were significantly different from the control group (p = 0.001). HGV co-infection is highly prevalent among northeastern Thai blood donors who are infected with HBV or HCV. The results also reveal that blood donors seronegative for HCV and HBV are a low risk group for HGV infection.

Cáncer de hígado y virus de las hepatitis B y C / Liver cancer and hepatitis B and C virus

Uno de los tumores hepáticos mas frecuentes, y de mayor malignidad es el carcinoma hepatocelular (CHC), el mismo que se encuentra estrechamente relacionado con el virus de la hepatitis B y C. Según estudios realizados, se ha demostrado que hay mayor incidencia de CHC en los portadores crónicos del HBsAg, aunque el mecanismo por el cual el virus de la hepatitis B puede desarrollar el CHC no está totalmente esclarecido; no obstante existe una relación directa con los procesos necroinflamatorios crónicos que el virus puede inducir. Es importante señalar también la incidencia del CHC por VHC ya que según estudios realizados utilizando sistemas ELISA, se demostró la presencia y replicación del virus en tejido hepático tumoral, confirmando de esta forma la asociación causal entre la infección por el VHC y CHC.En ensayos realizados en Taiwan e Italia, se observó que en pacientes en los que se detectaron simultáneamente ambos marcadores virales (HBsAg y el antiVHC), el riesgo de desarrollar CHC fue mayor, en comparación a aquellos que presentaron en forma aislada, la infección por uno de los 2 virus.Los mecanismos por los cuales la presencia de los virus de las hepatitis B y C promueven el desarrollo del CHC, no esta esclarecido totalmente; pero en la revisión de la literatura se plantean hipótesis importantes en cuanto al efecto oncogénico directo que pueden tener, así como los mecanismos indirectos que actúan por un incremento en la tasa de recambio de hepatocitos o por la producción de radicales libres.Estas son las razones por las cuales la Agencia Internacional para la investigación sobre el cáncer de la OMS se ha pronunciado sobre considerarlos, en especial al VHC, como agente carcinógeno en humanos.

One of the most common liver tumors, and of greatest malignancy, is the hepatocellular carcinoma (HCC), which is closely linked to Hepatitis B and C viruses.According to some studies, it has been demonstrated that the incidence of HC is highest among chronic carriers of HBAgs, although the mechanism by which the virus can lead to HCC is not well identified, thus there is a direct relationship among the chronic necroinflammatory processes that this virus can induce.It is also important to mention the incidence of HCC due to HCV, because there is studies in which the presence and replication of the virus in a normal liver tissue has been demonstrated by Elisa procedures, therefore confirming the causative association among virus infection and HCC.In some trials conducted in Taiwan and Italy, it was observed that the patients in which both viral markers (HBAgs and antiHCV) were detected simmoultaneously, the risk of developing HCC was higher, in comparison to those who presented isolated infection by one of the 2 viruses.The mechanisms by which the presence of both viruses, hepatitis B and C can promote the development of HCC is not totally determined, but the review of the literature suggests important hypothesis concerning a direct oncogenic effect, as well as indirect mechanisms, involving an increase in the exchange rate of hepatocites or the production of free radicals.These are the reasons for which the International Agency for the investigation of cancer of the WHO has pronounced into consideration, specially the HCV as a carcinogenic agent in humans.

GBV-C/HGV and HIV-1 coinfection

An interesting interaction pattern has been found between HIV-1 and GBV-C/HGV, resulting in protection against progression to AIDS. The mechanisms involved in this interaction remain to be clarified. We examined the current knowledge concerning this coinfection and developed hypotheses to explain its effects. A better understanding of this interaction could result in new concepts, which may lead to new strategies to control HIV-1 replication and progression to AIDS.

GB virus C/hepatitis G virus infection in dialysis patients and kidney transplant recipients in central Brazil

In order to investigate the prevalence of GB virus C (GBV-C)/hepatitis G virus (HGV) infection in dialysis patients and kidney transplant recipients in Central Brazil and also to analyze the virus genotypes distribution, a total of 123 patients including 98 on hemodialysis, 13 on continuous ambulatory peritoneal dialysis treatment, and 12 who received kidney transplantation were interviewed in one unit of dialysis treatment in Goiânia city. Blood samples were collected and serum samples tested for GBV-C/HGV RNA by polymerase chain reaction. Genotypes were determined by restriction fragment length polymorphism (RFLP) analysis. Eighteen samples were GBV-C/HGV RNA-positive, resulting in an overall prevalence of 14.6 percent (95 percent CI: 9.2-21.7). A high positivity for GBV-C/HGV RNA was observed in patients who had received kidney transplant (16.7 percent), followed by those on hemodialysis (15.3 percent), and peritoneal dialysis (7.7 percent). RFLP analysis revealed the presence of genotypes 1, 2, and 3 of GBV-C/HGV; more precisely, 9 (50 percent) samples were found belonging to the 2b subtype, 4 (22 percent) to the 2a subtype, 3 (17 percent) to genotype 1, and 2 (11 percent) to genotype 3. The present data indicate an intermediate prevalence of GBV-C/HGV infection among dialysis patients and kidney transplant recipients in Central Brazil. Genotype 2 (subtype 2b) seems to be the most prevalent GBV-C/HGV genotype in our region.

High prevalence of GB Virus C/Hepatitis G Virus RNA among Brazilian blood donors

The aim of this study was to investigate the presence of the Hepatitis G Virus on a population of blood donors from São Paulo, Brazil and to evaluate its association to sociodemographic variables. Two RT-PCR systems targeting the putative 5'NCR and NS3 regions were employed and the former has shown a higher sensitivity. The observed prevalence of HGV-RNA on 545 blood donors was 9.7 percent (CI 95 percent 7.4;12.5). Statistical analysis depicted an association with race/ethnicity, black and mulatto donors being more frequently infected; and also with years of education, less educated donors presenting higher prevalences. No association was observed with other sociodemographic parameters as age, gender, place of birth and of residence. DNA sequencing of nine randomly chosen isolates demonstrated the presence of genotypes 1, 2 and 3 among our population but clustering of these Brazilian isolates was not detected upon phylogenetic analysis

Prevalence and genotypes of GB Virus C/Hepatitis G virus among blood donors in Central Brazil

A survey was conducted in a blood donor population of Central Brazil aiming to investigate the prevalence of GB virus C (GBV-C)/hepatitis G virus (HGV) infection and also to analyze the virus genotypes distribution. A total of 241 voluntary blood donors were interviewed at the State Blood Bank in Goiânia, State of Goiás, Brazil. Blood samples were collected and serum samples tested for GBV-C/HGV RNA by polymerase chain reaction. Genotypes were determined by restriction fragment length polymorphism (RFLP) analysis. Seventeen samples were GBV-C/HGV RNA-positive, resulting in a prevalence of 7.1 percent (95 percent CI: 4.2-11.1). A significant trend of GBV-C/HGV RNA positivity in relation to age was observed, with the highest prevalence in donors between 29-39 years old. Ten infected individuals were characterized by reporting parenteral (30 percent), sexual (18 percent), both (6 percent) and intrafamiliar (6 percent) transmission. However, 7 (40 percent) GBV-C/HGV RNA-positive donors did not mention any potential transmission route. RFLP analysis revealed the presence of genotypes 1 and 2 of GBV-C/HGV; more precisely, 10 (58.9 percent) samples were found belonging to the 2b subtype, 4 (23.5 percent) to the 2a subtype, and 3 (17.6 percent) to genotype 1. The present data indicate an intermediate endemicity of GBV-C/HGV infection among this blood donor population, and a predominant circulation of genotype 2 (subtype 2b) in Central Brazil

Liver histology in co-infection of hepatitis C Virus (HCV) and hepatitis G virus (HGV)

As little is known about liver histology in the co-infection of hepatitis C virus (HCV) and hepatitis G virus (HGV), HGV RNA was investigated in 46 blood donors with hepatitis C, 22 of them with liver biopsy: co-infection HCV / HGV (n = 6) and HCV isolated infection (n = 16). Besides staging and grading of inflammation at portal, peri-portal and lobular areas (Brazilian Consensus), the fibrosis progression index was also calculated. All patients had no symptoms or signs of liver disease and prevalence of HGV / HCV co-infection was 15.2 percent. Most patients had mild liver disease and fibrosis progression index, calculated only in patients with known duration of infection, was 0.110 for co-infection and 0.130 for isolated HCV infection, characterizing these patients as "slow fibrosers". No statistical differences could be found between the groups, although a lesser degree of inflammation was always present in co-infection. In conclusion co-infection HCV / HGV does not induce a more aggressive liver disease, supporting the hypothesis that HGV is not pathogenic

Hepatitis G virus (HGV): current perspectives.

Five viruses are usually associated with hepatitis in humans: A-E. In addition to these viruses as aetiological agents of hepatitis, there remain a number of patients with hepatitis in whom no virus could be identified. It was therefore postulated that there may be other agents which may be causing hepatitis. Recently, two viruses have been associated with hepatitis: hepatitis G virus (HGV), and transfusion transmissible virus (TTV). Hepatitis G virus (HGV) is a single stranded RNA virus which represents a newly discovered virus belonging to the flavivirus family. HGV is distinct from hepatitis C virus (HCV) and the newly discovered GBV-A and GBV-B agents, while GBV-C represents an isolate of HGV. The structure of the HGV genome resembles that of HCV. HGV replicates in peripheral blood cells, while replication in liver cells has not been observed till date. Diagnosis of HGV infection is mainly by use of polymerase chain reaction (PCR), as serological techniques are still being developed. Epidemiological data indicate that the virus is prevalent throughout the world, including India and is transmitted via blood/blood products, sexually and vertically from infected mothers to children. The relationship between infection with the virus and presence of liver pathology is controversial and has not been proven beyond doubt, as majority of patients with HGV have no detectable evidence of disease.

Relationship between hepatitis G virus infection and hepatic failure / 中华肝脏病杂志

<p><b>OBJECTIVE</b>To study the pathogenic effect of hepatitis G virus (HGV) infection on hepatic failure.</p><p><b>METHODS</b>Using the RT-PCR and EIA techniques to detect HGV RNA and anti-HGV in sera of hepatic failure patients and compare them with their liver function and mortality rates.</p><p><b>RESULTS</b>There was no significant difference about the positive rates of HGV among acute hepatic failure, subacute hepatic failure and chronic hepatic failure groups (X(2)=2.54, P>0.05). The level of ALT in HGV-positive group was slightly lower than that in HGV-negative group. The concentration of bilirubin and globulin was higher in HGV-positive group than HGV-negative group, and the concentration of albumin in HGV-positive group was significantly lower than that in HGV-negative group (t=2.59, P<0.05). The mortality rate in HGV-positive group was significantly lower than that in HGV-negative group (X(2)=4.68, 0.01<P<0.05).</p><p><b>CONCLUSIONS</b>The virulence of HGV is mild, and the HGV infection does not aggravate hepatic failure.</p>